About Primmune
Primmune is a company based in San Diego (United States) founded in 2017 by Jim Appleman and Paulo Rangel. It operates as a HealthTech. Primmune has raised $60.03 million across 8 funding rounds from investors including McDermott International, Bioqube Ventures and CAM Capital. Primmune offers products and services including PRTX007. Primmune operates in a competitive market with competitors including TScan Therapeutics, Lyell Immunopharma, Hummingbird Bioscience, GigaGen and Shattuck Labs, among others.
- Headquarter San Diego, United States
- Founders Jim Appleman, Paulo Rangel
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Primmune Therapeutics, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$60.03 M (USD)
in 8 rounds
-
Latest Funding Round
$8.6 M (USD), Series B
Jan 26, 2026
-
Investors
McDermott International
& 8 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Primmune
Primmune offers a comprehensive portfolio of products and services, including PRTX007. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
PRTX007 is developed as a TLR7 agonist therapy.
Unlock access to complete
Unlock access to complete
Funding Insights of Primmune
Primmune has successfully raised a total of $60.03M across 8 strategic funding rounds. The most recent funding activity was a Series B round of $8.6 million completed in January 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 8
- Last Round Series B — $8.6M
-
First Round
First Round
(18 Oct 2017)
- Investors Count 9
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2026 | Amount | Series B - Primmune | Valuation |
investors |
|
| Nov, 2021 | Amount | Series A - Primmune | Valuation |
investors |
|
| Jan, 2021 | Amount | Series A - Primmune | Valuation | Bioqube Ventures |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Primmune
Primmune has secured backing from 9 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include McDermott International, Bioqube Ventures and CAM Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Life sciences investments are managed by Bioqube Ventures in Europe and the US to advance therapeutic assets and technologies.
|
Founded Year | Domain | Location | |
|
US focused venture capital firm
|
Founded Year | Domain | Location | |
|
Venture capital funding is provided by Samsara BioCapital in California.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Primmune
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Primmune
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Primmune Comparisons
Competitors of Primmune
Primmune operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as TScan Therapeutics, Lyell Immunopharma, Hummingbird Bioscience, GigaGen and Shattuck Labs, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
T cell-based treatments for immunological and oncological disorders are developed.
|
|
| domain | founded_year | HQ Location |
CAR-T and TIL immunotherapies for solid tumors are developed.
|
|
| domain | founded_year | HQ Location |
Antibody drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms.
|
|
| domain | founded_year | HQ Location |
An immunotherapy platform for oncology and other diseases is developed.
|
|
| domain | founded_year | HQ Location |
Viral immunotherapies are developed for cancer treatment.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Primmune
Frequently Asked Questions about Primmune
When was Primmune founded?
Primmune was founded in 2017.
Where is Primmune located?
Primmune is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Who is the current CEO of Primmune?
Paulo Rangel is the current CEO of Primmune. They have also founded this company.
Is Primmune a funded company?
Primmune is a funded company, having raised a total of $60.03M across 8 funding rounds to date. The company's 1st funding round was a Series A of $4M, raised on Oct 18, 2017.
What does Primmune do?
Primmune is engaged in the development of innovative therapies targeting cancer and viral infections through the activation of innate immunity. The company specializes in toll-like receptor 7 (TLR7) agonists, with its lead candidate PRTX007 being advanced for clinical trials in HPV-caused oropharyngeal cancer and hepatocellular carcinoma. Solutions are designed to stimulate plasmacytoid dendritic cells (pDCs) for systemic immune responses while minimizing proinflammatory side effects. Operations are centered in the healthcare and biotechnology sectors, addressing significant global health challenges.
Who are the top competitors of Primmune?
Primmune's top competitors include Hummingbird Bioscience, Lyell Immunopharma and GigaGen.
What products or services does Primmune offer?
Primmune offers PRTX007.
Who are Primmune's investors?
Primmune has 9 investors. Key investors include McDermott International, Bioqube Ventures, CAM Capital, Polaris Partners, and Samsara BioCapital.